Clinical Trials
2 trialsNCT05101109 2024-07-31
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
ABL Bio, Inc.
Phase 1 Completed
NCT02298387 2020-08-11
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
Mereo BioPharma
Phase 1 Completed